ZURICH (Reuters) – Roche’s immunotherapy Tecentriq combined with other drugs boosted lung cancer patients’ survival versus an older cocktail, the Swiss company’s latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb.
ZURICH (Reuters) – Roche’s immunotherapy Tecentriq combined with other drugs boosted lung cancer patients’ survival versus an older cocktail, the Swiss company’s latest trial success as it seeks an edge on Merck and Bristol-Myers Squibb.